Stock SGHT SIGHT SCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Sight Sciences, Inc.

Equities

SGHT

US82657M1053

Real-time Estimate Cboe BZX
Other stock markets
 16:21:09 17/05/2024 BST 		5-day change 1st Jan Change
5.425 USD -6.63% Intraday chart for Sight Sciences, Inc. +0.93% +5.04%
05-14 Transcript : Sight Sciences, Inc. Presents at Bank of America Health Care Conference 2024, May-14-2024 08:15 AM
05-03 Sight Sciences Shares Up After Q1 Net Loss Narrows, Revenue Rises; 2024 Revenue Outlook Reaffirmed MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference
AQ
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance
AQ
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery
AQ
Sight Sciences : SGHT Proxy - Apr'24
PU
Sight Sciences to Report First Quarter Financial Results on May 2, 2024
AQ
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
GL
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
AQ
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting
AQ
Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference
AQ
Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance
AQ
Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024
AQ
Sight Sciences Announces European Launch of the Ergo-Series of the OMNI Surgical System at the ESCRS Winter Meeting
AQ
Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting
AQ
Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital
AQ
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights
AQ
Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors
AQ
Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease
AQ
Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology
AQ
Sight Sciences : Material Event - Form 8-K
PU
Sight Sciences : Investor Presentation - Nov 23
PU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SGHT Stock
  4. News Sight Sciences, Inc.
  5. Press Releases